A phase 1/2 trial of brief androgen suppression and stereotactic radiation therapy (FASTR) for high-risk prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 92, Issue 4, 2015, Pages 856-862

  Bauman, Glenn ^a   Ferguson, Michelle ^b   Lock, Michael ^a   Chen, Jeff ^a   Ahmad, Belal ^a   Venkatesan, V M ^a   Sexton, Tracy ^a   D'Souza, David ^a   Loblaw, Andrew ^c   Warner, Andrew ^a   Rodrigues, George ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b Allan Blair Cancer Centre   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; TOXICITY; UROLOGY;

ANDROGEN SUPPRESSION; ELDERLY POPULATIONS; GASTROINTESTINAL; GENITOURINARY TOXICITIES; HIGH-RISK PROSTATE CANCERS; METHODS AND MATERIALS; PELVIC LYMPH NODES; TREATMENT MARGINS;

RADIOTHERAPY;

GONADORELIN AGONIST; ANTIANDROGEN; GONADORELIN;

ABDOMINAL CRAMP; ACUTE TOXICITY; ADJUVANT THERAPY; ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONE BEAM COMPUTED TOMOGRAPHY SCANNER; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FRAIL ELDERLY; FUNCTIONAL STATUS ASSESSMENT; GASTROINTESTINAL TOXICITY; GENITOURINARY TOXICITY; HIGH RISK PATIENT; HUMAN; INTESTINE OBSTRUCTION; LINEAR ACCELERATOR; LYMPH NODE IRRADIATION; MALE; MULTIMODALITY CANCER THERAPY; PELVIS LYMPH NODE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE; RADIATION INJURY; RADIATION RESPONSE; RECTUM CANCER; RECTUM HEMORRHAGE; STEREOTACTIC BODY RADIATION THERAPY; TOXICITY; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; URINE INCONTINENCE; UROGENITAL TRACT DISEASE; VULNERABLE ELDERLY SCALE; VULNERABLE POPULATION; AGONISTS; CLINICAL TRIAL; MIDDLE AGED; PROCEDURES; PROSTATIC NEOPLASMS; RADIATION DOSE FRACTIONATION; RADIOSURGERY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIOSURGERY;

EID: 84931578193     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2015.02.046     Document Type: Article

References (56)

1. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial Lancet 360 2002 103 106
2. P.R. Warde, M.D. Mason, and M.R. Sydes Intergroup randomized phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110; NCT00002633) [abstract] J Clin Oncol 28 Suppl. 18 2010 CRA4505
3. A.D. Sasse, E. Sasse, and A.M. Carvalho Androgenic suppression combined with radiotherapy for the treatment of prostate adenocarcinoma: A systematic review BMC Cancer 12 2012 54
4. A.K. Morgans, K.H. Fan, and T. Koyama Bone complications among prostate cancer survivors: Long-term follow-up from the prostate cancer outcomes study Prostate Cancer Prostatic Dis 17 2014 338 342
5. Ziehr DR, Chen MH, Zhang D, et al. Association of androgen deprivation therapy with excess cardiac-specific mortality in men with prostate cancer [e-pub ahead of print August 15, 2014]. BJU Int http://dx.doi.org/10.1111/bju.12905.
6. G. Rodrigues, H. Lukka, and P. Warde The prostate cancer risk stratification project: Database construction and risk stratification outcome analysis J Natl Compr Canc Netw 12 2014 60 69
7. D.J. Brenner, and E.J. Hall Fractionation and protraction for radiotherapy of prostate carcinoma Int J Radiat Oncol Biol Phys 43 1999 1095 1101
8. J. Fowler, R. Chapell, and M. Ritter Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 50 2001 1021 1031
9. G. Arcangeli, B. Saracino, and S. Gomellini A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer Int J Radiat Oncol Biol Phys 78 2010 11 18
10. G. Arcangeli, J. Fowler, and S. Gomellini Acute and late toxicity in a randomized trial of convential versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 79 2011 1013 1021
11. S. Arcangeli, L. Strigari, and S. Gomellini Updated results and patterns of failure in a randomized hypofractionated trial for high-risk prostate cancer Int J Radiat Oncol Biol Phys 854 2012 1172 1178
12. A. Pollack, A.L. Hanlon, and E.M. Horwitz Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionated dose escalation trial Int J Radiat Oncol Biol Phys 64 2006 518 526
13. A. Pollack, G. Walker, and M. Buyyounouski Five year results of a randomized external beam radiotherapy trial for prostate cancer [abstract] Int J Radiat Oncol Biol Phys 81 Suppl. 2011 S1
14. D.A. Kuban, G.M. Nogueras-Gonzales, and L. Hamblin Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation [abstract] Int J Radiat Oncol Biol Phys 78 Suppl. 2010 S58 S59
15. A. Sahgal, D. Roberge, and D. Schellenberg The Canadian Association of Radiation Oncology scope of practice guidelines for lung, liver, and spine stereotactic body radiotherapy Clin Oncol (R Coll Radiol) 24 2012 629 639
16. T.P. Boike, Y. Lotan, and L.C. Cho Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer J Clin Oncol 29 2011 2020 2026
17. B.L. Madsen, R.A. His, and H.T. Pham Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results Int J Radiat Oncol Biol Phys 67 2007 1099 1105
18. C.R. King, J.D. Brooks, and H. Gill Stereotactic body radiotherapy for localized prostate cancer: Interim results of a prospective phase II clinical trial Int J Radiat Oncol Biol Phys 73 2009 1043 1048
19. C.R. King, J.D. Brooks, and H. Gill Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer Int J Radiat Oncol Biol Phys 82 2012 877 882
20. C.I. Tang, D.A. Loblaw, and P. Cheung Phase I/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: Early results of pHART3 Clin Oncol (R Coll Radiol) 20 2008 729 737
21. C.R. King, D. Freeman, and I. Kaplan Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials Radiother Oncol 109 2013 217 221
22. A.J. Katz, M. Santoro, and F. Diblasio Stereotactic body radiotherapy for localized prostate cancer: Disease control and quality of life at 6 years Radiat Oncol 8 2013 118
23. D.E. Freeman, and C.R. King Stereotactic body radiotherapy for low-risk prostate cancer: Five-year outcomes Radiat Oncol 9 2011 3
24. L.N. Chen, S. Suy, and S. Uhm Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: The Georgetown University experience Radiat Oncol 9 2013 58
25. S.M. McBride, D.S. Wong, and J.J. Dombrowski Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: Preliminary results of a multi-institutional phase 1 feasibility trial Cancer 118 2012 3681 3690
26. M. Ritter, J. Forman, and P. Kupelian Hypofractionation for prostate cancer Cancer J 15 2009 1 6
27. O. Kaidar-Person, M. Roach 3rd, and G. Créhange Whole-pelvic nodal radiation therapy in the context of hypofractionation for high-risk prostate cancer patients: A step forward Int J Radiat Oncol Biol Phys 86 2013 600 605
28. A. Luciani, G. Ascione, and C. Bertuzzi Detecting disabilities in older patients with cancer: Comparison between comprehensive geriatric assessment and vulnerable elders survey-13 J Clin Oncol 28 2010 2046 2050
29. S.G. Mohile, K. Bylow, and W. Dale A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation Cancer 109 2007 802 810
30. A. Hsu, T. Pawlicki, and G. Luxton A study of image-guided intensity-modulated radiotherapy with fiducicals for localized prostate cancer including pelvic lymph nodes Int J Radiat Oncol Biol Phys 68 2007 898 902
31. G. Rodrigues, G. Bauman, and M. Lock Psychometric properties of a prostate cancer radiation late toxicity questionnaire Health Qual Life Outcomes 5 2007 29
32. L. Klotz, L. Zhang, and A. Lam Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer J Clin Oncol 28 2010 126 131
33. A. D'Amico, M. Chen, and A. Renshaw Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial J Am Med Assoc 299 2008 289 295
34. D.S. Sutton, W. Kong, and K. Ding The use of palliative radiotherapy for bone metastasis Radiother Oncol 97 2010 548 553
35. W. Kong, C.R. Jarvis, and D.S. Sutton The use of palliative whole brain radiotherapy in the management of brain metastases Clin Oncol (R Coll Radiol) 24 2012 e149 e158
36. L.F. Paszat, W.J. Mackillop, and P.A. Groome Radiotherapy for breast cancer in Ontario: Rate variation associated with region, age and income Clin Invest Med 21 1998 125 134
37. R. Miralbell, S.A. Roberts, and E. Zubizarreta Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: Alpha/beta Z 1.4 (0.9-2.2) Gy Int J Radiat Oncol Biol Phys 82 2012 e17 e24
38. P. Kupelian, V. Thakkar, and D. Khuntia Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Long-term outcomes Int J Radiat Oncol Biol Phys 63 2005 1463 1468
39. P. Kupelian, T. Willoughby, and C. Reddy Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic Experience Int J Radiat Oncol Biol Phys 68 2007 1424 1430
40. H. Quon, P.C. Cheung, and D.A. Loblaw Quality of life after hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer Int J Radiat Oncol Biol Phys 83 2012 617 623
41. H. Quon, P.C. Cheung, and D.A. Loblaw Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: Late toxicity Int J Radiat Oncol Biol Phys 82 2012 898 905
42. A.J. Katz, and J. Kang Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study Front Oncol 4 2014 240
43. T.J. Tan, S. Siva, and F. Foroudi Stereotactic body radiotherapy for primary prostate cancer: A systematic review J Med Imaging Radiat Oncol 58 2014 601 611
44. M. Anwar, V. Weinberg, and A.J. Chang Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: Comparison of PSA slope and nadir Radiat Oncol 9 2014 42
45. H.B. Musunuru, and A. Loblaw Clinical trials of stereotactic ablative radiotherapy for prostate cancer: Updates and future direction Future Oncol 11 2015 819 831
46. A.J. Katz, M. Santoro, and F. Diblasio Stereotactic body radiotherapy for localized prostate cancer: Disease control and quality of life at 6 years Radiat Oncol 8 2013 118
47. K. Bujko, M.P. Nowacki, and A. Nasierowska-Guttmejer Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer Br J Surg 93 2006 1215 1223
48. B. Cedermark, H. Johansson, and L.E. Rutqvist The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma. A prospective randomized trial. Stockholm Colorectal Cancer Study Group Cancer 75 1995 2269 2275
49. E. Kapiteijn, C.A. Marijnen, and I.D. Nagtegaal Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer N Engl J Med 345 2001 638 646
50. A. Martling, T. Holm, and H. Johansson The Stockholm II trial on preoperative radiotherapy in rectal carcinoma: Long-term follow-up of a population-based study Cancer 92 2001 896 902
51. J. Folkesson, H. Birgisson, and L. Pahlman Swedish Rectal Cancer Trial: Long lasting benefits from radiotherapy on survival and local recurrence rate J Clin Oncol 23 2005 5644 5650
52. ISRCTN Registry. Phase III study of hypofractionated radiotherapy of intermediate risk localized prostate cancer. Available at: http://www.controlled-trials.com/ISRCTN45905321. Accessed March 25, 2015.
53. A. D'Amico Stereotactic body radiation therapy versus intensity modulated radiation therapy for prostate cancer: Less cost at the expense of more genitourinary toxicity is a concerning but testable hypothesis J Clin Oncol 32 2014 1183 1185
54. M.I. Koukourakis, A. Papadopoulou, and I. Abatzoglou Postoperative pelvic hypofractionated accelerated radiotherapy with cytoprotection (HypoARC) for high-risk or recurrent prostate cancer Anticancer Res 32 2012 4561 4568
55. M.I. Koukourakis, S. Touloupidis, and J. Manavis Conformal hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC) for high risk prostatic carcinoma: Rationale, technique and early experience Anticancer Res 24 2004 3239 3243
56. D.W. Kim, L.C. Cho, and C. Straka Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer Int J Radiat Oncol Biol Phys 89 2014 509 517